1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Molecular-based Therapies 1.2.3 Steroid Therapy 1.2.4 Other 1.3 Market by Application 1.3.1 Global Duchenne Muscular Dystrophy Drugs Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Hospitals 1.3.3 Clinics 1.3.4 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Duchenne Muscular Dystrophy Drugs Market Perspective (2016-2027) 2.2 Duchenne Muscular Dystrophy Drugs Growth Trends by Regions 2.2.1 Duchenne Muscular Dystrophy Drugs Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Duchenne Muscular Dystrophy Drugs Historic Market Share by Regions (2016-2021) 2.2.3 Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Regions (2022-2027) 2.3 Duchenne Muscular Dystrophy Drugs Industry Dynamic 2.3.1 Duchenne Muscular Dystrophy Drugs Market Trends 2.3.2 Duchenne Muscular Dystrophy Drugs Market Drivers 2.3.3 Duchenne Muscular Dystrophy Drugs Market Challenges 2.3.4 Duchenne Muscular Dystrophy Drugs Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Duchenne Muscular Dystrophy Drugs Players by Revenue 3.1.1 Global Top Duchenne Muscular Dystrophy Drugs Players by Revenue (2016-2021) 3.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Players (2016-2021) 3.2 Global Duchenne Muscular Dystrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Duchenne Muscular Dystrophy Drugs Revenue 3.4 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio 3.4.1 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Drugs Revenue in 2020 3.5 Duchenne Muscular Dystrophy Drugs Key Players Head office and Area Served 3.6 Key Players Duchenne Muscular Dystrophy Drugs Product Solution and Service 3.7 Date of Enter into Duchenne Muscular Dystrophy Drugs Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Duchenne Muscular Dystrophy Drugs Breakdown Data by Type 4.1 Global Duchenne Muscular Dystrophy Drugs Historic Market Size by Type (2016-2021) 4.2 Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Type (2022-2027) 5 Duchenne Muscular Dystrophy Drugs Breakdown Data by Application 5.1 Global Duchenne Muscular Dystrophy Drugs Historic Market Size by Application (2016-2021) 5.2 Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America Duchenne Muscular Dystrophy Drugs Market Size (2016-2027) 6.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Type 6.2.1 North America Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021) 6.2.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027) 6.2.3 North America Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2027) 6.3 North America Duchenne Muscular Dystrophy Drugs Market Size by Application 6.3.1 North America Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021) 6.3.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027) 6.3.3 North America Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2027) 6.4 North America Duchenne Muscular Dystrophy Drugs Market Size by Country 6.4.1 North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2016-2021) 6.4.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2022-2027) 6.4.3 United States 6.4.4 Canada 7 Europe 7.1 Europe Duchenne Muscular Dystrophy Drugs Market Size (2016-2027) 7.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Type 7.2.1 Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021) 7.2.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027) 7.2.3 Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2027) 7.3 Europe Duchenne Muscular Dystrophy Drugs Market Size by Application 7.3.1 Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021) 7.3.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027) 7.3.3 Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2027) 7.4 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country 7.4.1 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2016-2021) 7.4.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size (2016-2027) 8.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Type 8.2.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021) 8.2.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027) 8.2.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2027) 8.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Application 8.3.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021) 8.3.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027) 8.3.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2027) 8.4 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region 8.4.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2016-2021) 8.4.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Duchenne Muscular Dystrophy Drugs Market Size (2016-2027) 9.2 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type 9.2.1 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021) 9.2.2 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027) 9.2.3 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2027) 9.3 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application 9.3.1 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021) 9.3.2 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027) 9.3.3 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2027) 9.4 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country 9.4.1 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2016-2021) 9.4.2 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size (2016-2027) 10.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Type 10.2.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021) 10.2.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027) 10.2.3 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2027) 10.3 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Application 10.3.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021) 10.3.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027) 10.3.3 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2027) 10.4 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country 10.4.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2016-2021) 10.4.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Biogen 11.1.1 Biogen Company Details 11.1.2 Biogen Business Overview 11.1.3 Biogen Duchenne Muscular Dystrophy Drugs Introduction 11.1.4 Biogen Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) 11.1.5 Biogen Recent Development 11.2 Roche 11.2.1 Roche Company Details 11.2.2 Roche Business Overview 11.2.3 Roche Duchenne Muscular Dystrophy Drugs Introduction 11.2.4 Roche Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) 11.2.5 Roche Recent Development 11.3 Daiichi Sankyo 11.3.1 Daiichi Sankyo Company Details 11.3.2 Daiichi Sankyo Business Overview 11.3.3 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Introduction 11.3.4 Daiichi Sankyo Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) 11.3.5 Daiichi Sankyo Recent Development 11.4 Pfizer 11.4.1 Pfizer Company Details 11.4.2 Pfizer Business Overview 11.4.3 Pfizer Duchenne Muscular Dystrophy Drugs Introduction 11.4.4 Pfizer Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) 11.4.5 Pfizer Recent Development 11.5 Cumberland Pharmaceuticals 11.5.1 Cumberland Pharmaceuticals Company Details 11.5.2 Cumberland Pharmaceuticals Business Overview 11.5.3 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction 11.5.4 Cumberland Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) 11.5.5 Cumberland Pharmaceuticals Recent Development 11.6 Santhera Pharmaceuticals 11.6.1 Santhera Pharmaceuticals Company Details 11.6.2 Santhera Pharmaceuticals Business Overview 11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction 11.6.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) 11.6.5 Santhera Pharmaceuticals Recent Development 11.7 Taiho Pharmaceutical 11.7.1 Taiho Pharmaceutical Company Details 11.7.2 Taiho Pharmaceutical Business Overview 11.7.3 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Introduction 11.7.4 Taiho Pharmaceutical Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) 11.7.5 Taiho Pharmaceutical Recent Development 11.8 Teijin Pharma 11.8.1 Teijin Pharma Company Details 11.8.2 Teijin Pharma Business Overview 11.8.3 Teijin Pharma Duchenne Muscular Dystrophy Drugs Introduction 11.8.4 Teijin Pharma Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) 11.8.5 Teijin Pharma Recent Development 11.9 Akashi Therapeutics 11.9.1 Akashi Therapeutics Company Details 11.9.2 Akashi Therapeutics Business Overview 11.9.3 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Introduction 11.9.4 Akashi Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) 11.9.5 Akashi Therapeutics Recent Development 11.10 Sarepta Therapeutics 11.10.1 Sarepta Therapeutics Company Details 11.10.2 Sarepta Therapeutics Business Overview 11.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Introduction 11.10.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) 11.10.5 Sarepta Therapeutics Recent Development 11.11 BioMarin 11.11.1 BioMarin Company Details 11.11.2 BioMarin Business Overview 11.11.3 BioMarin Duchenne Muscular Dystrophy Drugs Introduction 11.11.4 BioMarin Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) 11.11.5 BioMarin Recent Development 11.12 Fibrogen Inc 11.12.1 Fibrogen Inc Company Details 11.12.2 Fibrogen Inc Business Overview 11.12.3 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Introduction 11.12.4 Fibrogen Inc Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) 11.12.5 Fibrogen Inc Recent Development 11.13 Nobelpharma Co. Ltd 11.13.1 Nobelpharma Co. Ltd Company Details 11.13.2 Nobelpharma Co. Ltd Business Overview 11.13.3 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Introduction 11.13.4 Nobelpharma Co. Ltd Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) 11.13.5 Nobelpharma Co. Ltd Recent Development 11.14 Eloxx Pharmaceuticals 11.14.1 Eloxx Pharmaceuticals Company Details 11.14.2 Eloxx Pharmaceuticals Business Overview 11.14.3 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction 11.14.4 Eloxx Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) 11.14.5 Eloxx Pharmaceuticals Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of Molecular-based Therapies Table 3. Key Players of Steroid Therapy Table 4. Key Players of Other Table 5. Global Duchenne Muscular Dystrophy Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 6. Global Duchenne Muscular Dystrophy Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 7. Global Duchenne Muscular Dystrophy Drugs Market Size by Regions (2016-2021) & (US$ Million) Table 8. Global Duchenne Muscular Dystrophy Drugs Market Share by Regions (2016-2021) Table 9. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 10. Global Duchenne Muscular Dystrophy Drugs Market Share by Regions (2022-2027) Table 11. Duchenne Muscular Dystrophy Drugs Market Trends Table 12. Duchenne Muscular Dystrophy Drugs Market Drivers Table 13. Duchenne Muscular Dystrophy Drugs Market Challenges Table 14. Duchenne Muscular Dystrophy Drugs Market Restraints Table 15. Global Duchenne Muscular Dystrophy Drugs Revenue by Players (2016-2021) & (US$ Million) Table 16. Global Duchenne Muscular Dystrophy Drugs Market Share by Players (2016-2021) Table 17. Global Top Duchenne Muscular Dystrophy Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2020) Table 18. Ranking of Global Top Duchenne Muscular Dystrophy Drugs Companies by Revenue (US$ Million) in 2020 Table 19. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue (CR5 and HHI) & (2016-2021) Table 20. Key Players Headquarters and Area Served Table 21. Key Players Duchenne Muscular Dystrophy Drugs Product Solution and Service Table 22. Date of Enter into Duchenne Muscular Dystrophy Drugs Market Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Global Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021) (US$ Million) Table 25. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2016-2021) Table 26. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Type (2022-2027) (US$ Million) Table 27. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2022-2027) & (US$ Million) Table 28. Global Duchenne Muscular Dystrophy Drugs Market Size Share by Application (2016-2021) & (US$ Million) Table 29. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Application (2016-2021) Table 30. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Application (2022-2027) (US$ Million) Table 31. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Application (2022-2027) & (US$ Million) Table 32. North America Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021) (US$ Million) Table 33. North America Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027) & (US$ Million) Table 34. North America Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021) (US$ Million) Table 35. North America Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027) & (US$ Million) Table 36. North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2016-2021) & (US$ Million) Table 37. North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2022-2027) & (US$ Million) Table 38. Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021) (US$ Million) Table 39. Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027) & (US$ Million) Table 40. Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021) (US$ Million) Table 41. Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027) & (US$ Million) Table 42. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2016-2021) & (US$ Million) Table 43. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2022-2027) & (US$ Million) Table 44. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021) (US$ Million) Table 45. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027) & (US$ Million) Table 46. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021) (US$ Million) Table 47. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027) & (US$ Million) Table 48. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2016-2021) & (US$ Million) Table 49. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2022-2027) & (US$ Million) Table 50. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021) (US$ Million) Table 51. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027) & (US$ Million) Table 52. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021) (US$ Million) Table 53. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027) & (US$ Million) Table 54. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2016-2021) & (US$ Million) Table 55. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2022-2027) & (US$ Million) Table 56. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021) (US$ Million) Table 57. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027) & (US$ Million) Table 58. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021) (US$ Million) Table 59. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027) & (US$ Million) Table 60. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2016-2021) & (US$ Million) Table 61. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2022-2027) & (US$ Million) Table 62. Biogen Company Details Table 63. Biogen Business Overview Table 64. Biogen Duchenne Muscular Dystrophy Drugs Product Table 65. Biogen Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million) Table 66. Biogen Recent Development Table 67. Roche Company Details Table 68. Roche Business Overview Table 69. Roche Duchenne Muscular Dystrophy Drugs Product Table 70. Roche Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million) Table 71. Roche Recent Development Table 72. Daiichi Sankyo Company Details Table 73. Daiichi Sankyo Business Overview Table 74. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product Table 75. Daiichi Sankyo Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million) Table 76. Daiichi Sankyo Recent Development Table 77. Pfizer Company Details Table 78. Pfizer Business Overview Table 79. Pfizer Duchenne Muscular Dystrophy Drugs Product Table 80. Pfizer Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million) Table 81. Pfizer Recent Development Table 82. Cumberland Pharmaceuticals Company Details Table 83. Cumberland Pharmaceuticals Business Overview Table 84. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Table 85. Cumberland Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million) Table 86. Cumberland Pharmaceuticals Recent Development Table 87. Santhera Pharmaceuticals Company Details Table 88. Santhera Pharmaceuticals Business Overview Table 89. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Table 90. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million) Table 91. Santhera Pharmaceuticals Recent Development Table 92. Taiho Pharmaceutical Company Details Table 93. Taiho Pharmaceutical Business Overview Table 94. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product Table 95. Taiho Pharmaceutical Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million) Table 96. Taiho Pharmaceutical Recent Development Table 97. Teijin Pharma Company Details Table 98. Teijin Pharma Business Overview Table 99. Teijin Pharma Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million) Table 100. Teijin Pharma Recent Development Table 101. Akashi Therapeutics Company Details Table 102. Akashi Therapeutics Business Overview Table 103. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product Table 104. Akashi Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million) Table 105. Akashi Therapeutics Recent Development Table 106. Sarepta Therapeutics Company Details Table 107. Sarepta Therapeutics Business Overview Table 108. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product Table 109. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million) Table 110. Sarepta Therapeutics Recent Development Table 111. BioMarin Company Details Table 112. BioMarin Business Overview Table 113. BioMarin Duchenne Muscular Dystrophy Drugs Product Table 114. BioMarin Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million) Table 115. BioMarin Recent Development Table 116. Fibrogen Inc Company Details Table 117. Fibrogen Inc Business Overview Table 118. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Product Table 119. Fibrogen Inc Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million) Table 120. Fibrogen Inc Recent Development Table 121. Nobelpharma Co. Ltd Company Details Table 122. Nobelpharma Co. Ltd Business Overview Table 123. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Product Table 124. Nobelpharma Co. Ltd Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million) Table 125. Nobelpharma Co. Ltd Recent Development Table 126. Eloxx Pharmaceuticals Company Details Table 127. Eloxx Pharmaceuticals Business Overview Table 128. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Table 129. Eloxx Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million) Table 130. Eloxx Pharmaceuticals Recent Development Table 131. Research Programs/Design for This Report Table 132. Key Data Information from Secondary Sources Table 133. Key Data Information from Primary Sources List of Figures Figure 1. Global Duchenne Muscular Dystrophy Drugs Market Share by Type: 2020 VS 2027 Figure 2. Molecular-based Therapies Features Figure 3. Steroid Therapy Features Figure 4. Other Features Figure 5. Global Duchenne Muscular Dystrophy Drugs Market Share by Application: 2020 VS 2027 Figure 6. Hospitals Case Studies Figure 7. Clinics Case Studies Figure 8. Others Case Studies Figure 9. Duchenne Muscular Dystrophy Drugs Report Years Considered Figure 10. Global Duchenne Muscular Dystrophy Drugs Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 11. Global Duchenne Muscular Dystrophy Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 12. Global Duchenne Muscular Dystrophy Drugs Market Share by Regions: 2020 VS 2027 Figure 13. Global Duchenne Muscular Dystrophy Drugs Market Share by Regions (2022-2027) Figure 14. Global Duchenne Muscular Dystrophy Drugs Market Share by Players in 2020 Figure 15. Global Top Duchenne Muscular Dystrophy Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2020 Figure 16. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue in 2020 Figure 17. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2016-2021) Figure 18. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2022-2027) Figure 19. North America Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 20. North America Duchenne Muscular Dystrophy Drugs Market Share by Type (2016-2027) Figure 21. North America Duchenne Muscular Dystrophy Drugs Market Share by Application (2016-2027) Figure 22. North America Duchenne Muscular Dystrophy Drugs Market Share by Country (2016-2027) Figure 23. United States Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 24. Canada Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 25. Europe Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 26. Europe Duchenne Muscular Dystrophy Drugs Market Share by Type (2016-2027) Figure 27. Europe Duchenne Muscular Dystrophy Drugs Market Share by Application (2016-2027) Figure 28. Europe Duchenne Muscular Dystrophy Drugs Market Share by Country (2016-2027) Figure 29. Germany Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 30. France Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 31. U.K. Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 32. Italy Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 33. Russia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 34. Nordic Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 35. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Share by Type (2016-2027) Figure 37. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Share by Application (2016-2027) Figure 38. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Share by Region (2016-2027) Figure 39. China Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 40. Japan Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 41. South Korea Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 42. Southeast Asia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 43. India Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 44. Australia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 45. Latin America Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. Latin America Duchenne Muscular Dystrophy Drugs Market Share by Type (2016-2027) Figure 47. Latin America Duchenne Muscular Dystrophy Drugs Market Share by Application (2016-2027) Figure 48. Latin America Duchenne Muscular Dystrophy Drugs Market Share by Country (2016-2027) Figure 49. Mexico Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 50. Brazil Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 51. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 52. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Share by Type (2016-2027) Figure 53. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Share by Application (2016-2027) Figure 54. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Share by Country (2016-2027) Figure 55. Turkey Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 56. Saudi Arabia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 57. UAE Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 58. Biogen Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021) Figure 59. Roche Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021) Figure 60. Daiichi Sankyo Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021) Figure 61. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021) Figure 62. Cumberland Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021) Figure 63. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021) Figure 64. Taiho Pharmaceutical Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021) Figure 65. Teijin Pharma Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021) Figure 66. Akashi Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021) Figure 67. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021) Figure 68. BioMarin Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021) Figure 69. Fibrogen Inc Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021) Figure 70. Nobelpharma Co. Ltd Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021) Figure 71. Eloxx Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021) Figure 72. Bottom-up and Top-down Approaches for This Report Figure 73. Data Triangulation Figure 74. Key Executives Interviewed

Biogen Roche Daiichi Sankyo Pfizer Cumberland Pharmaceuticals Santhera Pharmaceuticals Taiho Pharmaceutical Teijin Pharma Akashi Therapeutics Sarepta Therapeutics BioMarin Fibrogen Inc Nobelpharma Co. Ltd Eloxx Pharmaceuticals